PRELUDE THERAPEUTICS INC's ticker is PRLD and the CUSIP is 74065P101. A total of 61 filers reported holding PRELUDE THERAPEUTICS INC in Q1 2021. The put-call ratio across all filers is - and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $33,709,601 | -31.3% | 10,909,256 | 0.0% | 0.72% | -19.6% |
| Q2 2023 | $49,091,652 | -14.2% | 10,909,256 | +8.7% | 0.89% | -20.7% |
| Q1 2023 | $57,226,239 | -5.6% | 10,039,691 | 0.0% | 1.12% | -3.2% |
| Q4 2022 | $60,639,734 | -8.6% | 10,039,691 | 0.0% | 1.16% | -5.8% |
| Q3 2022 | $66,362,000 | +26.6% | 10,039,691 | 0.0% | 1.23% | +29.7% |
| Q2 2022 | $52,407,000 | -24.3% | 10,039,691 | 0.0% | 0.95% | -15.4% |
| Q1 2022 | $69,274,000 | -44.6% | 10,039,691 | 0.0% | 1.12% | -30.1% |
| Q4 2021 | $124,994,000 | -60.2% | 10,039,691 | 0.0% | 1.61% | -53.4% |
| Q3 2021 | $313,740,000 | +9.2% | 10,039,691 | 0.0% | 3.45% | +18.6% |
| Q2 2021 | $287,436,000 | -33.9% | 10,039,691 | 0.0% | 2.91% | -28.5% |
| Q1 2021 | $435,020,000 | -61.0% | 10,039,691 | -35.6% | 4.07% | -58.3% |
| Q4 2020 | $1,115,813,000 | +137.5% | 15,594,877 | 0.0% | 9.76% | +65.3% |
| Q3 2020 | $469,874,000 | – | 15,594,877 | – | 5.91% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Orbimed Advisors | 10,039,691 | $69,274,000 | 1.12% |
| Baker Brothers Advisors | 10,123,824 | $69,854,000 | 0.40% |
| HHLR ADVISORS, LTD. | 583,333 | $4,025,000 | 0.08% |
| Rock Springs Capital Management LP | 368,959 | $2,546,000 | 0.06% |
| PDT Partners, LLC | 71,822 | $496,000 | 0.04% |
| Virtus ETF Advisers LLC | 13,048 | $90,000 | 0.04% |
| Corton Capital Inc. | 10,918 | $75,000 | 0.03% |
| GSA CAPITAL PARTNERS LLP | 23,201 | $160,000 | 0.02% |
| OCCUDO QUANTITATIVE STRATEGIES LP | 24,238 | $167,000 | 0.01% |
| IndexIQ Advisors LLC | 56,750 | $392,000 | 0.01% |